Mark Rogge

Mark Rogge

Takeda Pharmaceutical Company Limited - Osaka / Japan
Others
AD Scientific Index ID: 4406034
武田薬品工業株式会社
person_outline Mark Rogge's MOST POPULAR ARTICLES
1-) Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses Antimicrobial agents and chemotherapy 41 (10), 2256-2260, 1997
2-) Effect of food and a monoglyceride emulsion formulation on danazol bioavailability The Journal of Clinical Pharmacology 33 (4), 381-386, 1993
3-) Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses Antimicrobial agents and chemotherapy 36 (5), 993-996, 1992
4-) Targeting RNA: a transformative therapeutic strategy Clinical and translational science 12 (2), 98-112, 2019
5-) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysisH Lee, HC Kimko, M Rogge, D Wang, I Nestorov, CC PeckClinical Pharmacology & Therapeutics 73 (4), 348-365, 20031422003